Version: 1.0.0 | Published: 8 Oct 2024 | Updated: 229 days ago
Documentation
Description:
CASPS is a two-arm, randomised, double-blind, placebo-controlled, Phase II trial of cediranib in ASPS patients. The primary objective is to evaluate the efficacy of cediranib by measuring the percentage change in the sum of target marker lesion diameters from randomisation to week 24 compared to placebo. Secondary objectives include: progression-free survival, overall survival and safety and tolerability of cediranib in ASPS patients. Tissue markers of tumour response, circulating markers of angiogenesis, and changes in circulating endothelial cells/precursor cells in response to cediranib will be explored. Thirty six patients with progressive, metastatic, histologically confirmed ASPS will be recruited. Patients will be randomised to 24 weeks of blinded cediranib or placebo, after which treatment will be unblinded and all patients offered open-label cediranib until objective disease progression, or death if sooner.
Coverage
Spatial:
United Kingdom,England
Provenance
Temporal
Start Date:
01 January 2010
Time Lag:
Variable
Accessibility
Access
Access Rights:
Please contact the publisher using Contact Point details provided
Access Request Cost:
Not specified
Delivery Lead Time:
Not applicable
Data Controller:
The Institute of Cancer Research
Usage
Resource Creators:
In Progress
Format and Standards
Vocabulary Encoding Schemes:
LOCAL
Languages:
en
Formats:
In Progress